menu
    • menu

    Company profile for Longboard Pharmaceuticals

    NEW Drugs in Dev: 3
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Longboard Pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Longboard’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmen...
    Longboard Pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Longboard’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Longboard PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6154 Nancy Ridge Drive, San Diego, CA 92121
    Telephone
    Telephone
    (619) 592-9775
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.longboardpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck acquires all outstanding shares of Longboard Pharma
    Lundbeck acquires all outstanding shares of Longboard Pharma

    04 Dec 2024

    // PRESS RELEASE

    https://www.lundbeck.com/us/newsroom/2024/lundbeck-to-acquire-longboard-pharmaceuticals-in-a-strategic-deal

    PRESS RELEASE
    04 Dec 2024
    Share Share
    Longboard Launches Phase 3 DEEp OCEAN Study for Bexicaserin in DEEs
    Longboard Launches Phase 3 DEEp OCEAN Study for Bexicaserin in DEEs

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112523128/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share
    Longboard Pharma Reports Q3 2024 Results & Corporate Updates
    Longboard Pharma Reports Q3 2024 Results & Corporate Updates

    07 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241107787183/en

    BUSINESSWIRE
    07 Nov 2024
    Share Share
    Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
    Denmark's Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal

    15 Oct 2024

    // REUTERS

    https://www.reuters.com/markets/deals/lundbeck-buy-longboard-pharma-26-billion-deal-2024-10-14/

    REUTERS
    15 Oct 2024
    Share Share
    Longboard Pharmaceuticals Announces Inducement Grants Under Rule
    Longboard Pharmaceuticals Announces Inducement Grants Under Rule

    04 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241004357703/en

    BUSINESSWIRE
    04 Oct 2024
    Share Share
    Longboard Initiates Phase 3 Study In Dravet Syndrome
    Longboard Initiates Phase 3 Study In Dravet Syndrome

    26 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240926926536/en

    BUSINESSWIRE
    26 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search